Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) Director Suzanne Ildstad sold 12,942 shares of Talaris Therapeutics stock in a transaction dated Wednesday, June 14th. The shares were sold at an average price of $2.49, for a total value of $32,225.58. Following the completion of the transaction, the director now directly owns 3,771,392 shares in the […]
Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) Director Suzanne Ildstad sold 12,942 shares of the company’s stock in a transaction dated Wednesday, June 14th. The stock was sold at an average price of $2.49, for a total value of $32,225.58. Following the sale, the director now owns 3,771,392 shares in the company, valued at approximately […]
Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) Director Suzanne Ildstad sold 16,870 shares of Talaris Therapeutics stock in a transaction on Monday, June 12th. The stock was sold at an average price of $2.59, for a total transaction of $43,693.30. Following the sale, the director now directly owns 3,798,542 shares of the company’s stock, valued […]
Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) Director Suzanne Ildstad sold 16,870 shares of the business’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $2.59, for a total transaction of $43,693.30. Following the completion of the sale, the director now owns 3,798,542 shares in the company, […]
Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) Director Suzanne Ildstad sold 7,841 shares of the company’s stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $2.52, for a total transaction of $19,759.32. Following the completion of the transaction, the director now owns 2,782,023 shares in […]